Clinical Pharmacology of GLP-1 RAs The approval of the first GLP-1 RA, exenatide, by the FDA in 2005 marked a significant advancement in treating diabetes and obesity
Considering the emerging link between impaired cerebellar function and mania, and that decreased serum BDNF is a biomarker of bipolar disorder, the decrease in cerebellar BDNF expression in the Camkk2 and Camk4 null mice suggests that defects in CaMKK2-CaMK4 signalling within the cerebellum may be involved in triggering manic behaviour [46,47,48,49]
55.6% of GLP-1 Users Use Semaglutide Drugs Out of all surveyed, 55.6% of GLP-1 users used Semaglutide
Key Takeaways GLP-1s may support heart health in ways that go beyond weight loss, including effects on inflammation, blood vessels, and HFpEF symptoms
This article explores how GLP-1 medications have helped to improve some patients relationship to exercise